dr. K. (Karina) Meijer

Head, Division of Haemostasis and Thrombosis

dr. K. (Karina) Meijer
E-mail:
k.meijer umcg.nl

Research

  1. 2017
  2. Schulman, S., & Meijer, K. (2017). Hypercoagulable States. In S. McKean, D. D. Dressler, J. Ross, J. Ginsberg, & D. Brotman (Eds.), Principles and Practice of Hospital Medicine (2de ed.)
  3. 2016
  4. Hazendonk, H., Fijnvandraat, K., Lock, J., Driessens, M., van der Meer, F., Meijer, K., ... Opti-Clot Study Grp (2016). A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 101(10), 1159-1169. https://doi.org/10.3324/haematol.2015.136275
  5. van Galen, K. P. M., Meijer, K., Vogely, H. C., Eikenboom, J., Schutgens, R. E. G., Cnossen, M. H., ... WiN Study Grp (2016). Joint surgery in von Willebrand disease: a multicentre cross-sectional study. Haemophilia, 22(2), 256-262. https://doi.org/10.1111/hae.12834
  6. Hazendonk, H. C. A. M., Lock, J., Mathot, R. A. A., Meijer, K., Peters, M., Laros-Van Gorkom, B. A. P., ... Cnossen, M. H. (2016). Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 14(3), 468-478. https://doi.org/10.1111/jth.13242
  7. van Velzen, A. S., Eckhardt, C. L., Streefkerk, N., Peters, M., Hart, D. P., Hamulyak, K., ... INSIGHT Study Grp (2016). The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thrombosis and Haemostasis, 115(3), 543-550. https://doi.org/10.1160/TH15-03-0212
  8. 2015
  9. Hazendonk, H. C. A. M., van Moort, I., Fijnvandraat, K., Kruip, M. J. H. A., Laros-van Gorkom, B. A. P., van der Meer, F. J. M., ... Cnossen, M. H. (2015). The "OPTI-CLOT" trial. Thrombosis and Haemostasis, 114(3), 639-644. https://doi.org/10.1160/TH14-11-0925
  10. Sanders, Y. V., van der Bom, J. G., Isaacs, A., Cnossen, M. H., de Maat, M. P. M., Laros-van Gorkom, B. A. P., ... WiN Study Grp (2015). CLEC4M and STXBP5 gene variations contribute to vonWillebrand factor level variation in von Willebrand disease. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13(6), 956-966. https://doi.org/10.1111/jth.12927
  11. Sanders, Y. V., Groeneveld, D., Meijer, K., Fijnvandraat, K., Cnossen, M. H., van der Bom, J. G., ... WiN Study Grp (2015). von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 125(19), 3006-3013. https://doi.org/10.1182/blood-2014-09-603241
  12. van Galen, K. P. M., Sanders, Y. V., Vojinovic, U., Eikenboom, J., Cnossen, M. H., Schutgens, R. E. G., ... WiN Study Grp (2015). Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia, 21(3), E185-E192. https://doi.org/10.1111/hae.12670
  13. 2014
  14. Sanders, Y. V., Giezenaar, M. A., Laros-van Gorkom, B. A. P., Meijer, K., van der Bom, J. G., Cnossen, M. H., ... WiN Study Grp (2014). von Willebrand disease and aging: an evolving phenotype. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 12(7), 1066-1075. https://doi.org/10.1111/jth.12586
  15. Loomans, J. I., Van Velzen, A. S., Eckhardt, C. L., Peters, M., Astermark, J., Brons, P. P., ... Fijnvandraat, K. (2014). Von Willebrand Factor antigen and age explain variation in baseline FVIII:C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser). Haemophilia, 20, 56.
  16. Eckhardt, C. L., Loomans, J. I., Velzen, A. S. V., Peters, M., Astermark, J., Brons, P. P., ... INSIGHT Study Grp (2014). Clinical presentation of inhibitor development in non-severe hemophilia A: half of patients have high titer inhibitors and present with bleeding complications. Haemophilia, 20, 55-55.
  17. Van Velzen, A. S., Eckhardt, C. L., Streefkerk, N., Peters, M., Astermark, J., Brons, P. P., ... Fijnvandraat, K. (2014). Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis. Haemophilia, 20, 49. https://doi.org/10.1111/hae.12400
  18. Loomans, J. I., Van Velzen, A. S., Eckhardt, C. L., Peters, M., Astermark, J., Brons, P. P., ... Fijnvandraat, K. (2014). Prediction of DDAVP response in 850 non-severe hemophilia A patients. Haemophilia, 20, 55. https://doi.org/10.1111/hae.12400
  19. Loomans, J. I., Van Velzen, A. S., Eckhardt, C. L., Peters, M., Astermark, J., Brons, P. P., ... Insight Rise Study Grp (2014). Von Willebrand Factor antigen and age explain variation in baseline FVIII: C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser). Haemophilia, 20, 56-56.
  20. Sanders, Y., de Wee, E., Meijer, K., Eikenboom, J., van der Bom, J., Fijnvandraat, K., ... Leebeek, F. (2014). De ziekte van Von Willebrand in Nederland: de WiN studie. Nederlands Tijdschrift voor Geneeskunde, 158, A6518.
  21. 2013
  22. Eckhardt, C. L., Van Velzen, A. S., Peters, M., Astermark, J., Brons, P. P., Castaman, G., ... Fijnvandraat, K. (2013). Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia a. Blood, 122(11), 1954-1962. https://doi.org/10.1182/blood-2013-02-483263

ID: 116299